The increase in international food trade and travel has dramatically increased the global incidences of Salmonellosis. In the light of widespread resistance to frontline antibiotics, oral vaccines remain the most reliable alternative. In this study, the fusion protein, r-BL was rationally constructed by splicing the Salmonella Typhimurium sseB and ompL genes through G4S linker by over-lap extension PCR. The oral coadministration of r-BL with B. abortus U-Omp19 protein with known protease inhibitor activity resulted in significant increase of mucosal IgA titres to antilog 4.5051 (p < 0.0001) and 4.806 (p < 0.0001) in the fecal samples and intestinal washes respectively. Antibody isotyping of the intestinal washes demonstrated increase in mucosal IgM, IgG1 and IgG2a isotypes also and demonstrated a significant reduction in fecal shedding of S. Typhimurium in challenge study. The r-BL + U-Omp19 treated mice demonstrated a complete termination of Salmonella fecal shedding by the 12^th day of challenge as compared to other study groups. In summary, the bivalent protein r-BL when administered with the mucosal adjuvant U-Omp19 was successful in triggering mucosal arm of the immune system which forms the first line of defence in combating the infections caused by the enteric pathogen like Salmonella.

国际食品贸易和旅行的增加极大地增加了全球沙门氏菌病的发病率。鉴于对一线抗生素的广泛耐药性，口服疫苗仍然是最可靠的替代方案。本研究通过重叠延伸PCR将鼠伤寒沙门氏菌sseB和ompL基因通过G4S接头合理构建融合蛋白r-BL 。r-BL 与流产芽孢杆菌的口服联合给药具有已知蛋白酶抑制剂活性的 U-Omp19 蛋白导致粪便样品和肠道冲洗液中的粘膜 IgA 滴度显着增加，分别为 4.5051 (p < 0.0001) 和 4.806 (p < 0.0001)。肠道冲洗液的抗体同种型显示黏膜 IgM、IgG1 和 IgG2a 同种型也增加，并表明S 的粪便脱落显着减少。挑战研究中的鼠伤寒。r-BL + U-Omp19 处理的小鼠在^第12 天完全停止了沙门氏菌的粪便脱落。与其他研究组相比，挑战日。总之，当与粘膜佐剂 U-Omp19 一起给药时，二价蛋白 r-BL 成功地触发了免疫系统的粘膜臂，这是对抗沙门氏菌等肠道病原体引起的感染的第一道防线。